Posted by: bigdaddyc25 In reply to: None Date:8/14/2006 6:20:29 PM Post #of 36053
UPDATE
Hey guys, I am not going to talk about any more PR predictions. I will however, post VERY CLEAR information from my discussions with Steve Burg and others at XKEM. I just spoke with Steve for half an hour about a number of topics.
1) Why has there been no update PR on revenues as he had discussed with several of us last week?
He said that last week he was trying to get something out to us. Unfortunately, the decision makers on what was ALLOWED to be released in terms of revenue based information, were out of town working on other important matters. They were unable to review the information put together by Steve. He said that those decision makers are BACK this week. He also said that he has done everything in his power to get them to dedicate some serious time today and tomorrow figuring out exactly what information to provide us with. He said that he has emphasized the need to communicate with shareholders NOW.
2) Any update on the UPS loan? What is taking so long?
He has heard from the folks working on the loan TODAY, that the loan is VERY CLOSE to being closed, and that they believe this is IMMINENT.
3) Status of construction of new facility.
Construction of new facility is on plan, and they do not anticipate any delays.
4) What are your thoughts on current PPS drop? I said to him, that at this pace, it will be less that $0.02 by the end of the week. I do not believe this will happen, but I was looking for a reaction from him, and trying to communicate the need for information.
He said that the drop will end, and in his opinion, the PPS will not see those levels.
5) When did sales begin? I told him, that some here posted that sales began 1 week ago. This would be impossible, because the July 26 PR had said sales had already begun.
He said he was wrong in saying 1 week, and that the sales had begun 3 to 4 weeks ago.
That is it for now guys. I will continue to support XKEM IR function, until they get their own crap together.
later BigD
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
Member Rated: 2 Icon 1 posted August 14, 2006 10:52 PM Profile for money 76 Send New Private Message Edit/Delete Post Reply With Quote we have heard all this crap earlier from steve.
words do not mean anything where is the action.
looks like they r just fooling us . urll guys have waited for long . live with hopes and steves crap.
i am out of it .
Hey Money if you are out of this why are you still here posting and bashing the stock? That makes absolutely no sense at all. If you sold out then you should move on. If you think you are being subtle your not. It is obvious your bashing.
Posts: 12 | From: South Carolina | Registered: Aug 2006
| IP: Logged |
posted
i am no basher . i am a newbie just started trading 3 months back
but i am pissed with this companys way of dealing with shareholders
where is the pr .i am trying to help newbies like me not to invest in such a scam . dont feel bad if u have done ur dd thats good .
u have never posted anything before in this . how come u have jumped into it . hehe fishy.
Posts: 417 | From: grand cayman | Registered: May 2006
| IP: Logged |
quote:Originally posted by money 76: i am no basher . i am a newbie just started trading 3 months back
but i am pissed with this companys way of dealing with shareholders
where is the pr .i am trying to help newbies like me not to invest in such a scam . dont feel bad if u have done ur dd thats good .
u have never posted anything before in this . how come u have jumped into it . hehe fishy.
if you want to help the newbies go to the other boards of each symbol than went down today, that would be a good help too. LOL
Posts: 4112 | Registered: Jun 2006
| IP: Logged |
posted
sure . i will do that also . let me help them firstly with a bigger scam than i will handle the small ones. lol.......
Posts: 417 | From: grand cayman | Registered: May 2006
| IP: Logged |
quote:Originally posted by money 76: yeah they have the evidence which they have kept with themselves..
nicosan and the world does not know about it .
nigeria ......................
lol grow up stop dreaming.
chart says we may drop lower from technicals alone, I sold a lot because of the negative divergence on the weekly, but it isnt a scam.. they have a great product. just need to ride ot this bump.
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
quote:Originally posted by fatbacker: money 76 Member
Member Rated: 2 Icon 1 posted August 14, 2006 10:52 PM Profile for money 76 Send New Private Message Edit/Delete Post Reply With Quote we have heard all this crap earlier from steve.
words do not mean anything where is the action.
looks like they r just fooling us . urll guys have waited for long . live with hopes and steves crap.
i am out of it .
Hey Money if you are out of this why are you still here posting and bashing the stock? That makes absolutely no sense at all. If you sold out then you should move on. If you think you are being subtle your not. It is obvious your bashing.
Why is everyone that says something negative about a stock a "basher" or a "manipulator trying to make money by shorting the stock!"?
I find this logic a little ill conceived and slightly manic and hysterical. Not to mention the derivative of paranoia.
I think if people get frustrated and sell and talk smack about a security it's their business.
If other people join in the hysteria and negative attitude, well that's just the mob mentality of human beings kicking in.
You can't blame people for following the crowd, now can you?
-------------------- Paranoia, fear and greed is good. Posts: 137 | From: Private | Registered: Jul 2006
| IP: Logged |
posted
Welcome aboard Palimike. It's hard to resist at these levels. I am in, and probably will buy more. If we get good news this this baby should move up quite well.
Posts: 190 | From: South Bay Califonia | Registered: Apr 2006
| IP: Logged |
posted
Why is everyone that says something negative about a stock a "basher" or a "manipulator trying to make money by shorting the stock!"?
He is not only being negative but he is not basing his accusations with any proof or links or any type of DD what-so-ever. He comes in here and tells everyone this is just a scam and with no basis. He also posted that he is out of it which means he really has no point to post his bad feelings towards this stock what so ever. If you have something to say about a stock you are in then that is fine but use your DD to show it so we can all learn from it either good or bad. He is bashing. If you read what the definition of bashing is you will see what he is doing is bashing. Google the word and see what you come up with.
Posts: 12 | From: South Carolina | Registered: Aug 2006
| IP: Logged |
posted
Xechem Chairman Responds to Shareholder Questions Regarding NICOSAN(TM) Progress and Sales Forecasts
NEW BRUNSWICK, N.J., Aug 16, 2006 (BUSINESS WIRE) -- The Chairman of Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, responded today to a number of questions posed by investors and others in the business community concerning the status of its operations in the aftermath of the approval of NICOSAN(TM), its sickle cell drug, by Nigerian regulators on July 3rd, 2006. Some of the questions posed to the company and answered by Dr. Pandey are the following:
Status of Production Facility
Q1: Xechem has reported that its Sickle Cell Drug, NICOSAN(TM), is being produced in limited quantities at its pilot scale facility in Abuja, and that construction has now begun on its full scale facility at the same location. When do you expect the full scale facility to be completed and at what cost?
A1: We estimate that the construction of the new facility will be completed in approximately nine to twelve months, subject to timely receipt of the required funds, and the facility will be fully operational then. Our current estimate is that the total cost of the new facility, including the cost of the required machinery and equipment, will be approximately $12 to $15 million, of which over $5 million has already been invested by the Company.
Expected Sources of Funding
Q2: What are the sources of the expected funding to finance the capital expenditures?
A2: In the past several weeks, we received a loan from NEXIM Bank of Nigeria for 150 million Naira (USD $1.2 million). The bulk of those proceeds have been earmarked for the initial phase of construction, and that work has recently begun. NEXIM has been an extremely supportive lender that likes very much what Xechem is doing in Nigeria and has expressed a strong interest in investing significantly more money into Xechem's operations there. In fact, advanced discussions are now underway with NEXIM officials concerning a substantial new loan, the proceeds of which would be used primarily for constructing the buildings for the new commercial scale facility. We are also continuing to aggressively pursue an approximately $8 to $9 million loan through the U.S. Export-Import Bank Loan Guarantee Program.
Q3: Can you provide a report on the status of the Ex-Im loan and the likelihood that it will close in the near future?
A3: As with any significant commercial loan to a company at our stage of development, issues arise during the course of negotiation and due diligence that can affect the timing of any proposed transaction. This was especially true prior to July 2006, when we received regulatory approval from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC). That approval added quite a bit of credibility to our efforts, particularly in procuring the required local Nigerian bank guarantee, and has seemed to accelerate the pace of negotiations with the various parties involved with the Ex-Im guaranteed loan. Although certainly there are no assurances as to when or if this loan will close, I believe we have satisfied all of the statutory and other requirements for the transaction and my sense is that this loan has an excellent chance of being approved in the near future.
Q4: Do you believe the government of Nigeria may step up and agree to provide financial support to Xechem in one form or another?
A4: In my judgment, the government of Nigeria has an incentive to offer financial support to Xechem for at least three important reasons. First, we have licensed our product from Nigeria's National Institute for Pharmaceutical Research and Development (NIPRD), which stands to benefit directly from our financial success through the gross royalty they will receive from the sale of our product. Second, there is no place in the world where NICOSAN(TM) is more desperately needed than Nigeria and I believe that the government has a strong incentive on humanitarian grounds to help insure that the drug reaches as many of its citizens as can be accomplished. And third, Nigeria is working very hard to improve its image internationally and to promote corporate investment, especially by American companies. The government of Nigeria knows that Xechem is being closely watched by investors and others in the business community who want to see if an American company like Xechem can be truly successful in Nigeria. For all of these reasons, I believe that the government of Nigeria would consider offering Xechem substantial financial support in one form or another under the right circumstances .
Q5: Has Xechem already approached the Nigerian government about the possibility of providing Xechem some form of financial accommodation?
A5: As with many aspects of the development of our business, until our drug was formally approved by the regulators in Nigeria, it was impossible to have meaningful dialogue concerning possible governmental support for Xechem in whatever form. Now that the drug has been approved, those doors have been opening, in some case widely, and that has been the case concerning possible governmental support. While I cannot speak to the details of those discussions or comment on the possible timing or likelihood of working directly with the government to support our operations financially, I can say that we are having high level conversations with government officials concerning a possible pre-purchase of large scale quantities of our product for distribution by the government in the country's national hospitals.
Current and Projected Sales Activity
Q6: Turning to the drug itself, have sales of the product begun and, if so, how is the drug being distributed?
A6: We have begun sales of the product on a limited basis in Abuja. Because we are producing pilot scale quantities which are insufficient to meet the expected demand for the product, we have strictly limited distribution of the drug so that, at present, it can only be acquired at Xechem Nigeria's headquarters at Sheda Science and Technology Complex (SHESTCO), Abuja. Soon, we expect to open three to four satellite offices in Abuja. These measures will last until the full scale facility is completed when we will turn to more traditional avenues of marketing and distribution throughout Nigeria and beyond. Keep in mind that once on the medicine, a patient must continue taking it on a daily basis without interruption in order for the drug to be effective. One of our big concerns is making sure that once a patient begins taking the medicine, that person will have uninterrupted access to the drug going forward.
Q7: How many patients do you expect to serve before the completion of the full-scale facility?
A7: Based on the quantities of the finished product now on hand and our current small-scale production capability, we project that we will be able to meet the needs of approximately 20,000 patients per month on an annualized basis pending completion of the full-scale facility.
Q8: What is the current price for the drug and what sales volume do you forecast for this initial period prior to full-scale production?
A8: We are currently charging 3000 Naira (USD $23) per month for adult patients and 2400 Naira (USD $18.50) per month for children. If we meet our target of supplying 20,000 patients per month on average during the first year, this will result in annual sales of approximately $5 million during this period of limited production capability. That number could be significantly higher if, as we expect, we are successful in achieving some incremental increase in capacity between now and the time the full-scale facility is completed.
Q9: Once the expanded production facility is completed, what do you feel is the market potential for this drug?
A9: There are approximately 4 million people in Nigeria alone afflicted with Sickle Cell Disease, of whom we believe upwards of 50% live in urban or quasi-urban areas where average income levels are believed to be sufficiently high to absorb the retail cost of the product. Realistically, we believe we should be able to penetrate more than half of that segment of the market over a five year period, which would result in estimated annual revenues to Xechem Nigeria of approximately $200 million at today's prices. And that is for Nigeria alone. Needless to say, down the road, we expect to generate additional revenues from sales of the product throughout Africa, not to mention India and the Middle East and, of course, Europe and the United States. Also, these figures do not take into account additional sales that may be possible to poorer segments of Nigerian society as part of a pre-purchase or other support program with the government of Nigeria.
Q10: Can you speak to the substantial decline in the price of Xechem stock that has occurred since the launch?
A10: There are many theories on that, and it's probably best for me not to address them directly. What I do feel comfortable in saying is that we have something very special going on in Nigeria right now and have unquestionably accomplished a great deal in getting to this point in spite of the many obstacles in our path. I am confident that as we secure one or more traditional bank type financings and move forward in the implementation of our business plan, things will change markedly for Xechem and its shareholders. My message to our shareholders is this: the patient investor will be rewarded as we progress toward full scale production of this historical drug.
About NICOSAN(TM) NICOSAN(TM) is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.
About Xechem
Xechem International is a development stage biopharmaceutical company working on anticancer, antiviral (including AIDS), antifungal, antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem will now turn to the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties.
SOURCE: Xechem International, Inc.
CONTACT: Xechem International, Inc. Stephen Burg, 707-425-8855
Posts: 2660 | From: Pennyland USA | Registered: Jun 2004
| IP: Logged |
Maybe you think this PR is fake and it is just a trick to get us to buy more stock.
Posts: 12 | From: South Carolina | Registered: Aug 2006
| IP: Logged |
posted
Just a note fatbacker, it doesn't say anything we don't already know does it? Probably better putting out a pr than doing one of those m 1 interviews though.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
This message to shareholders boosts my confidence 10x of what it is already at. I think that this is a very fair and noble PR.
Posts: 37 | From: Pacific Palisades/Boulder | Registered: Jun 2006
| IP: Logged |
"She (Minister for Finance) expressed satisfaction that government support for private sector-led investment in science and technology had begun to yield fruits, citing the development of the drug Nicosan Xychem, for sickle-cell anaemia, as a classic case of public-private sector partnership and therefore called for closer cooperation between the two sectors."
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
posted
when they complete the new facility this will be huge,they are supplying what they got at the moment , but there is a real market for this drug, and yes the drug is real too
Q8: What is the current price for the drug and what sales volume do you forecast for this initial period prior to full-scale production?
A8: We are currently charging 3000 Naira (USD $23) per month for adult patients and 2400 Naira (USD $18.50) per month for children. If we meet our target of supplying 20,000 patients per month on average during the first year, this will result in annual sales of approximately $5 million during this period of limited production capability. That number could be significantly higher if, as we expect, we are successful in achieving some incremental increase in capacity between now and the time the full-scale facility is completed.
Q9: Once the expanded production facility is completed, what do you feel is the market potential for this drug?
A9: There are approximately 4 million people in Nigeria alone afflicted with Sickle Cell Disease, of whom we believe upwards of 50% live in urban or quasi-urban areas where average income levels are believed to be sufficiently high to absorb the retail cost of the product. Realistically, we believe we should be able to penetrate more than half of that segment of the market over a five year period, which would result in estimated annual revenues to Xechem Nigeria of approximately $200 million at today's prices. And that is for Nigeria alone. Needless to say, down the road, we expect to generate additional revenues from sales of the product throughout Africa, not to mention India and the Middle East and, of course, Europe and the United States. Also, these figures do not take into account additional sales that may be possible to poorer segments of Nigerian society as part of a pre-purchase or other support program with the government of Nigeria.
Q10: Can you speak to the substantial decline in the price of Xechem stock that has occurred since the launch?
A10: There are many theories on that, and it's probably best for me not to address them directly. What I do feel comfortable in saying is that we have something very special going on in Nigeria right now and have unquestionably accomplished a great deal in getting to this point in spite of the many obstacles in our path. I am confident that as we secure one or more traditional bank type financings and move forward in the implementation of our business plan, things will change markedly for Xechem and its shareholders. My message to our shareholders is this: the patient investor will be rewarded as we progress toward full scale production of this historical drug.
Posts: 4112 | Registered: Jun 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Cool]](cool.gif)
